Compare VanEck Gold Miners ETF (GDX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs Recursion Pharmaceuticals Inc — how do they compare? VanEck Gold Miners ETF trades at $88.64 (market cap $25.65B), while Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B). The key difference: VanEck Gold Miners ETF is far larger — about 12× Recursion Pharmaceuticals Inc's market cap, and VanEck Gold Miners ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Gold Miners ETF for 76 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| GDX | RXRX | |
|---|---|---|
Market Cap | $25.65B | $2.14B |
Volume | 16,534,046 | 30,789,535 |
52-Week High | $115.84 | $6.79 |
52-Week Low | $68.28 | $2.84 |
Typical Hold Time | 76 Days | 22 Days |
Sector | — | Health |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDX, the VanEck Gold Miners ETF, trades at $85.46, down 3.13% amid a bearish technical signal with 13 sell signals from moving averages. Recent news highlights pressure on gold miners from rising interest rates and silver's sharp decline, though some analysts see value in the sell-off. Key support lies at $84, with resistance at $86-87. The ETF offers exposure to gold mining equities but lacks disclosed fundamental ratios in this snapshot.
The outlook for GDX hinges on gold price direction and interest rate trends, with risks including metal volatility and macroeconomic headwinds. Opportunities exist if gold rebounds, but investor caution is warranted given technical weakness and mixed sentiment from institutional flows.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
